Ann Radiat Ther Oncol | Volume 1, Issue 2 | Case Report | Open Access

A Long Time Surviving Patients with Diagnosis of Advanced Small Cell Lung Cancer

Francesco Perri*

Department of Oncology, San Giuseppe Moscati Hospital, Canada

*Correspondance to: Francesco Perri 

Fulltext PDF


Background: Small cell lung cancer (SCLC) is a poor prognosis tumor characterized by neuroendocrine histology, arising from the lung. It often is diagnoses as advanced disease and its prognosis is grim. Standard therapy options are represented by chemoradiation in case of intrathoracic disease or chemotherapy alone if the disease is diagnosed as metastatic. Platinum derived compounds associated with etoposide represent the standard of therapy in patients with SCLC, but albeit a good overall response rate (the sum of partial and complete clinical responses) which reaches the 80%, almost all patients relapse within 1 year.5-Year overall survival is anecdotal and no targeted therapies demonstrated to be valid in clinical trials.
Case Report: We described the case of a 58-year old male patients suffering for an advanced SCLC treated with six cycles of cisplatin-etoposide chemotherapy, followed by thorax and brain radiation therapy, who obtained a complete response lasting for 3 years. Conclusions: SCLC remains a poor prognosis disease and standard treatment options have not significantly changed in the last decades. Targeted therapy has not a role at present, but in the next future, immunotherapy can ameliorate the prognosis of these patients.


SCLC; Chemotherapy; Long survival; Radiotherapy


Perri F. A Long Time Surviving Patients with Diagnosis of Advanced Small Cell Lung Cancer. Ann Radiat Ther Oncol. 2018; 1(2): 1014.

Subscribe to Our Newsletter